164 related articles for article (PubMed ID: 37140852)
1. Point-of-care testing: a disposable label-free electrochemical CA125 and HE4 immunosensors for early detection of ovarian cancer.
Bilgi Kamaç M; Altun M; Yılmaz M; Yılmaz Aktan A; Aktan S; Sezgintürk MK
Biomed Microdevices; 2023 May; 25(2):18. PubMed ID: 37140852
[TBL] [Abstract][Full Text] [Related]
2. A label-free dual immunosensor for the simultaneous electrochemical determination of CA125 and HE4 biomarkers for the early diagnosis of ovarian cancer.
Bilgi Kamaç M; Altun M; Yilmaz M; Sezgintürk MK
Anal Bioanal Chem; 2023 Apr; 415(9):1709-1718. PubMed ID: 36719438
[TBL] [Abstract][Full Text] [Related]
3. A disposable impedimetric immunosensor for the analysis of CA125 in human serum samples.
Yılmaz M; Bilgi M
Biomed Microdevices; 2024 Jan; 26(1):8. PubMed ID: 38180587
[TBL] [Abstract][Full Text] [Related]
4. Role of Defects of Carbon Nanomaterials in the Detection of Ovarian Cancer Cells in Label-Free Electrochemical Immunosensors.
Runprapan N; Wang FM; Ramar A; Yuan CC
Sensors (Basel); 2023 Jan; 23(3):. PubMed ID: 36772172
[TBL] [Abstract][Full Text] [Related]
5. Ultrasensitive immunoassay of carcinoma antigen 125 in untreated human plasma samples using gold nanoparticles with flower like morphology: A new platform in early stage diagnosis of ovarian cancer and efficient management.
Hasanzadeh M; Sahmani R; Solhi E; Mokhtarzadeh A; Shadjou N; Mahboob S
Int J Biol Macromol; 2018 Nov; 119():913-925. PubMed ID: 30081127
[TBL] [Abstract][Full Text] [Related]
6. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
7. Electrochemical quantum dots-based magneto-immunoassay for detection of HE4 protein on metal film-modified screen-printed carbon electrodes.
Cadkova M; Kovarova A; Dvorakova V; Metelka R; Bilkova Z; Korecka L
Talanta; 2018 May; 182():111-115. PubMed ID: 29501129
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
10. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.
Gąsiorowska E; Michalak M; Warchoł W; Lemańska A; Jasiński P; Spaczyński M; Nowak-Markwitz E
Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831
[TBL] [Abstract][Full Text] [Related]
11. Ultrasensitive and label-free electrochemical immunosensor for the detection of the ovarian cancer biomarker CA125 based on CuCo-ONSs@AuNPs nanocomposites.
Mu W; Wu C; Wu F; Gao H; Ren X; Feng J; Miao M; Zhang H; Chang D; Pan H
J Pharm Biomed Anal; 2024 Jun; 243():116080. PubMed ID: 38479306
[TBL] [Abstract][Full Text] [Related]
12. The Establishment of an HE4-CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer.
Zhang Q; Wang CR; Yu JP; Ma Q; Xu WW
J Clin Lab Anal; 2016 Sep; 30(5):709-18. PubMed ID: 26990679
[TBL] [Abstract][Full Text] [Related]
13. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.
Ortiz-Muñoz B; Aznar-Oroval E; García García A; Covisa Peris A; Perez Ballestero P; Sanchez Yepes M; Garcia Lozano T; Illueca Ballester C; García Garcia E
Tumour Biol; 2014 Jul; 35(7):7249-58. PubMed ID: 24771264
[TBL] [Abstract][Full Text] [Related]
14. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.
Xi QP; Pu DH; Lu WN
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous Detection of Ovarian Cancer-Concerned HE4 and CA125 Markers Based on Cu Single-Atom-Triggered CdS QDs and Eu MOF@Isoluminol ECL.
Tang Y; Liu Y; Xia Y; Zhao F; Zeng B
Anal Chem; 2023 Mar; 95(10):4795-4802. PubMed ID: 36867090
[TBL] [Abstract][Full Text] [Related]
16. A label-free electrochemical immunosensor based on a gold-vertical graphene/TiO
Chen Z; Li B; Liu J; Li H; Li C; Xuan X; Li M
Mikrochim Acta; 2022 Jun; 189(7):257. PubMed ID: 35701556
[TBL] [Abstract][Full Text] [Related]
17. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
18. CA125 and HE4: Measurement Tools for Ovarian Cancer.
Zhao T; Hu W
Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726
[TBL] [Abstract][Full Text] [Related]
19. Boron nitride nanosheet modified label-free electrochemical immunosensor for cancer antigen 125 detection.
Öndeş B; Evli S; Uygun M; Aktaş Uygun D
Biosens Bioelectron; 2021 Nov; 191():113454. PubMed ID: 34171737
[TBL] [Abstract][Full Text] [Related]
20. Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia.
Winarto H; Laihad BJ; Nuranna L
Asian Pac J Cancer Prev; 2014; 15(5):1949-53. PubMed ID: 24716917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
